Ironwood Pharmaceuticals (formerly Microbia) is dedicated to creating, developing, and commercializing innovative human medicines, and has clinical stage programs in GI disorders and dyslipidemia. The Company discovered, developed and is commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Ironwood is also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract.

TypePublic
HQCambridge, US
Size (employees)730 (est)+9%
Websiteironwoodpharma.com
Ironwood Pharmaceuticals is headquartered in Cambridge, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Ironwood Pharmaceuticals

Peter Hecht

Peter Hecht

CEO
Brian Cali

Brian Cali

Senior Vice President, R&D Strategy and External Innovation
Gina Consylman

Gina Consylman

Senior Vice President, Chief Financial Officer
Mark Currie

Mark Currie

Senior Vice President, Chief Scientific Officer, and President of R&D
Halley Gilbert

Halley Gilbert

Senior Vice President & Chief Legal Officer
Bill Huyett

Bill Huyett

COO
Show more

Ironwood Pharmaceuticals Office Locations

Ironwood Pharmaceuticals has an office in Cambridge
Cambridge, (HQ)
301 Binney St
Show all (1)
Report incorrect company information

Ironwood Pharmaceuticals Financials and Metrics

Ironwood Pharmaceuticals Revenue

Ironwood Pharmaceuticals's revenue was reported to be $298.28 m in FY, 2017
USD

Revenue (Q3, 2018)

65.7m

Net income (Q3, 2018)

(174.4m)

EBIT (Q3, 2018)

(169.1m)

Market capitalization (4-Dec-2018)

2.0b

Closing stock price (4-Dec-2018)

12.7

Cash (30-Sep-2018)

141.6m
Ironwood Pharmaceuticals's current market capitalization is $2 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

22.9m76.4m149.6m274.0m298.3m

Revenue growth, %

234%96%83%

Cost of goods sold

12.0k

Gross profit

149.5m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

52.2m65.1m86.8m69.2m81.1m65.7m

Cost of goods sold

2.0m1.9m10.5m12.0k8.2m

General and administrative expense

30.3m29.9m29.3m28.5m30.3m33.0m30.4m36.2m36.9m45.0m55.6m57.8m61.8m61.9m68.4m55.2m

R&D expense

23.0m27.1m22.1m25.1m26.6m28.6m25.8m31.8m31.7m37.5m33.7m37.3m37.1m36.5m38.9m46.8m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

75.5m74.3m261.3m54.0m125.7m

Accounts Receivable

513.0k10.0k2.9m933.0k3.2m

Inventories

22.1m10.6m6.3m1.1m735.0k

Current Assets

229.1m289.7m500.2m380.2m311.6m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

144.5m205.1m95.4m51.3m63.7m256.5m248.1m280.9m277.3m182.9m133.3m182.1m162.6m144.8m145.4m141.6m

Accounts Receivable

125.0k13.0k380.0k862.0k1.1m2.6m908.0k1.3m1.2m1.2m4.0m4.3m5.0m6.7m10.2m

Inventories

20.6m23.4m13.0m13.0m5.0m1.5m1.1m479.0k1.7m1.1m76.0k

Current Assets

275.8m371.3m325.8m304.1m263.9m527.0m505.8m495.7m386.1m382.8m357.9m341.5m314.1m275.7m279.5m248.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(272.8m)(189.6m)(142.7m)(81.7m)(116.9m)

Depreciation and Amortization

11.7m12.3m11.6m10.3m8.4m

Inventories

(11.9m)(3.9m)2.6m(3.1m)346.0k

Accounts Payable

(11.7m)1.4m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(61.8m)(49.6m)(110.0m)(152.0m)(33.2m)(81.2m)(128.6m)(13.3m)(35.0m)(68.2m)(52.5m)(96.7m)(129.0m)(43.1m)(92.5m)(266.9m)

Depreciation and Amortization

3.1m6.2m9.4m6.0m8.8m2.8m5.3m7.5m2.9m4.8m6.6m1.8m3.5m4.8m

Inventories

(1.3m)272.0k224.0k5.0m4.0k71.0k1.1m1.1m(768.0k)

Accounts Payable

(8.0m)(7.7m)2.8m
Show all financial metrics
Report incorrect company information

Ironwood Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Ironwood Pharmaceuticals News and Updates

Report incorrect company information

Ironwood Pharmaceuticals Blogs

Ironwood Pharmaceuticals to Present at 27th Annual Credit Suisse Healthcare Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 8, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 27 th Annual Credit Suisse Healthcare Conference on Wednesday, November 14 th , 2018 at 2:15 p.m. Mountain Time ( 4:15 p.m.

Ironwood Pharmaceuticals Provides Third Quarter 2018 Investor Update

– LINZESS ® (linaclotide) U.S. net sales increased 7% to $205 million in 3Q 2018 vs 3Q 2017 – – Ironwood revenue of $66 million in 3Q 2018, which includes a $30 million reduction due to LINZESS change in estimate as reported to Ironwood by Allergan – – Received Fast Track Designation for

Ironwood Pharmaceuticals to Host Third Quarter 2018 Investor Update Call

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 25, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2018 investor update conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, November 6, 2018 . Individuals interested in participating in the

Ironwood Pharmaceuticals Presenting IW-3718 and Linaclotide Data at the American College of Gastroenterology 2018 Annual Scientific Meeting

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 8, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced the presentation of clinical data for IW-3718 and linaclotide from the company and its collaborators during the American College of Gastroenterology

Eric Joseph

Eric Joseph Neil.Lawrence@… Wed, 09/26/2018 - 14:19 Eric Joseph J.P. Morgan

Ironwood Pharmaceuticals Announces FDA Fast Track Designation for Praliciguat for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

– Praliciguat Phase II trial in HFpEF continues to enroll patients with topline data expected in the second half of 2019 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 13, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that the U.S.
Show more

Ironwood Pharmaceuticals Company Life and Culture

Report incorrect company information

Ironwood Pharmaceuticals Frequently Asked Questions

  • Who are Ironwood Pharmaceuticals key executives?

    Ironwood Pharmaceuticals's key executives are Peter Hecht, Brian Cali and Gina Consylman.

  • How many employees does Ironwood Pharmaceuticals have?

    Ironwood Pharmaceuticals has 730 employees.

  • What is Ironwood Pharmaceuticals revenue?

    Latest Ironwood Pharmaceuticals annual revenue is $298.3 m.

  • What is Ironwood Pharmaceuticals revenue per employee?

    Latest Ironwood Pharmaceuticals revenue per employee is $408.6 k.

  • Who are Ironwood Pharmaceuticals competitors?

    Competitors of Ironwood Pharmaceuticals include Kiniksa Pharmaceuticals, Sartorius Stedim BioOutsource and Neurosearch.

  • Where is Ironwood Pharmaceuticals headquarters?

    Ironwood Pharmaceuticals headquarters is located at 301 Binney St, Cambridge.

  • Where are Ironwood Pharmaceuticals offices?

    Ironwood Pharmaceuticals has an office in Cambridge.

  • How many offices does Ironwood Pharmaceuticals have?

    Ironwood Pharmaceuticals has 1 office.